The company develops new drug candidates to treat Alzheimer’s disease (AD), other diseases of the central nervous system (CNS) and various types of cancer.
Anavex president and chief executive officer Christopher Missling said: "We are delighted to have the active drug product (API) manufactured and available for our Phase 2a trial."
The company is seeking to begin clinical trials with ANAVEX PLUS for the treatment of AD, which remains on track to start in 2014 with data from the first part of the trial expected to be released in mid 2015.
ANAVEX 2-73 is an orally available drug candidate developed for the treatment of AD through potential disease modification.
The drug candidate has undergone an initial Phase I human clinical trial and was well tolerated in doses up to 55mg.
Results from preclinical studies indicate that ANAVEX 2-73 shows anti-amnesic and neuroprotective properties.